Spesolimab is a humanized monoclonal immunoglobulin G1 antibody and is the first therapy to target the IL-36 pathway, a key driver of GPP disease processes. Spesolimab has an acceptable safety profile ...

The Tp-e interval, and Tp-e/QT Tp-e/QTc ratios were significantly prolonged in patients with wild-type ATTR-CM compared to healthy people. Electrocardiographic (ECG) parameters are prolonged in ...

The disease burden of pulmonary arterial hypertension (PAH) is still high in China and India, according to a new study.

Intravenously administered zaltenibart was shown to be safe and effective in phase 2 clinical trials. Enrollment is under way to recruit patients for a phase 3 study designed to assess intravascular ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a rare acquired autoimmune neurological disorder in which both T-cell-mediated and humoral immune mechanisms target healthy myelinated ...

A systematic review and meta-analysis of trials in CIDP was published in 2023, studying the outcomes of patients including at least 2 years of follow-up. Studies conducted over 1 to 2 years ...

Treatment discontinuation rates were similar to those in the placebo group, and no notable safety imbalances were observed for serious adverse events. Nerandomilast, an investigational oral ...

Gastrointestinal involvement in systemic mastocytosis (SM) is a common complication and often leads to endoscopic findings. Gastrointestinal (GI) symptoms are the second most frequent clinical ...

The modified Spinal Muscular Atrophy Functional Rating Scale (SMAFRS) is a psychometrically stable and unidimensional outcome measure, even though certain items are misfitting like those related to ...

This case report corresponds with others suggesting that tobacco use and asbestos exposure may be associated with the pathophysiology of IgG4-RD. An elderly male patient with a history of smoking and ...

Baby marijuana plants grow under artificial light at the giant indoor cultivation facility of Curio Wellness in Timonium, Maryland. (Photo by Larry Luxner) Huntington disease is one of the many ...

In CIDP, SOC therapies (immunoglobulins/corticosteroids) are burdensome, have variable efficacy, and significant side-effects. Two phase 3 clinical trials, MOBILIZE ...